We've detected an Ad Blocker in your browser.
Please disable or pause the Ad Blocker and refresh the page to be able to register and access the website normally.
A TMA initiative in partnership with Radcliffe Cardiology
A global virtual event dedicated to the latest heart failure treatment strategies to support better patient outcomes
Overview
Translational Medicine Academy (TMA) in partnership with Radcliffe Cardiology are delighted to introduce e-SPACE Heart Failure 2022 to be held 14–15 October.
e-SPACE Heart Failure 2022 will deliver best-in-class free-to-access virtual education. Bringing together thought-leaders from across the globe and broadcast over three time-zones – Asia, Europe, and the Americas – e-SPACE Heart Failure 2022 will both optimise geographical reach whilst delivering both global and regional insight.
A thoughtfully curated programme will support the exploration of how leading experts are implementing the new heart failure guidelines into clinical practice, as well as aiding the discovery of the latest information on patient profiling in heart failure for tailoring medical therapy.
Course leadership Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE), Dr Javed Butler (Baylor Scott and White Research Institute, Texas, US), Prof Andrew Coats (University of Warwick, Coventry, UK) and Dr Shelley Zieroth (University of Manitoba, Manitoba, CA) will lead an interactive programme of plenary sessions, meet the experts, case discussions and industry sponsored sessions focusing on the patient journey.
This year’s e-SPACE Heart Failure will, for the first time, bring together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
Underpinned by this combined expertise in educational content and delivery, and led by an international faculty of global standing, e-SPACE Heart Failure 2022 promises to be the widest reaching and most engaging to date.
REGISTER FREE NOW
REGISTER NOW
Register Now
Share this event:
Course Leadership
Prof Stefan Anker
CHAIR
Charité Campus Virchow-Klinikum, Berlin, DE
Prof Stefan Anker studied medicine at Charité Medical School of Humboldt-University Berlin, Germany from 1987 to 1993. He went on to complete his PhD at the National Heart and Lung Institute of Imperial College London, United Kingdom, in 1998. Since then, he has had teaching appointments in several countries including the UK, Germany, Australia and Italy.
He has worked as a Junior Professor and then as Professor for Charité Campus Virchow-Klinikum since 2002. He is a member of and serves on the Boards of several academic organizations, including the Board of the Heart Failure Association of the European Society of Cardiology and the Editorial Board of the Journal of Cachexia, Sarcopenia and Muscle (SCWD). He is also a member of the German Centre for Cardiovascular Research (DZHK).
More info 
Less info
Dr Javed Butler
CO-CHAIR
Baylor Scott and White Research Institute, Texas, US
Dr Javed Butler is Professor and Chair of the Department of Medicine at University of Mississippi Medical Center in Jackson Mississippi, and also Patrick H Lehan Chair of Cardiovascular Research. He is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He has authored more than 900 peer-reviewed publications. Previously, he was Director of the Division of Cardiovascular Medicine and Co-director of the Heart Institute at State University of New York (SUNY) Stony Brook University.
More info
Less info
Prof Andrew Coats
CHAIR
University of Warwick, Coventry, UK
Prof Andrew Coats is President of the Heart Failure Association and Professor of Cardiology, University of Warwick, Coventry, UK. He is an Australian-British academic cardiologist and inventor with a main interest of heart failure.
From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine of the University of Sydney. Prof Coats is Editor-in-Chief of the Cardiac Failure Review editorial board.
More info
Less info
Dr Shelley Zieroth
CHAIR
University of Manitoba, Manitoba, CA
Dr Shelley Zieroth is at SBH Heart Failure and Transplant Clinics and serves as Head of the Medical Heart Failure Program, WRHA Cardiac Sciences Program, and as Associate Professor of the Section of Cardiology at the University of Manitoba, Canada. Dr Zieroth attended medical school at the University of Manitoba, where she went on to train in internal medicine and cardiology. She completed her postdoctoral clinical fellowship, specializing in advanced heart failure and cardiac transplant, at Toronto General Hospital. She has lectured internationally on the subject of heart failure. Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.
More info
Less info
Faculty
Prof Magdy Abdelhamid
Kasr Al-Ainy School of Medicine, Cairo, EG
Prof William Abraham
Ohio State University College of Medicine. Ohio, US
Dr Marianna Adamo
University of Brescia, Brescia, IT
Dr Sajid Ansari
S.S Heart Care Centre, Uttar Pradesh, IN
Dr John Atherton
Royal Brisbane and Women’s Hospital, Brisbane, AU
Dr Cecilia Bahit
INECO Neurociencias Oroño, Santa Fe, AR
Prof George L. Bakris
University of Chicago Medicine, Illinois, US
Prof Johann Bauersachs
Hannover Medical School, Hannover, DE
Prof Antoni Bayes-Genis
Hospital Germans Trias i Pujol, Barcelona, ES
Dr Biykem Bozkurt
Baylor College of Medicine, Texas, US
Jasper J. Brugts
Erasmus University Medical Centre, Rotterdam, NL
Prof John Camm
St George's University of London, London, UK
Prof Antonio Ceriello
IRCCS MultiMedica, Milan, IT
Prof Ovidiu Chioncel
University of Medicine Carol Davila, Bucharest, RO
Dr Vijay Chopra
Max Super Specialty Hospital, New Delhi, IN
Prof John Cleland
University of Glasgow, Glasgow, UK
Prof Marisa G. Crespo-Leiro
University of A Coruña, A Coruña, ES
Dr Kieran Docherty
University of Glasgow, Glasgow, UK
Dr Justin Ezekowitz
University of Alberta, Alberta, CA
Prof Gerasimos Filippatos
National and Kapodistrian University of Athens, Athens, GR
Dr Marat Fudim
Duke University, North Carolina, US
Giuseppe Galati
San Raffaele Research Hospital, Milan, IT
Dr Stephen Greene
Duke University School of Medicine, North Carolina, US
Dr Sivadasanpillai Harikrishnan
Sree Chitra Institute, Trivandrum, IN
Prof Ewa Jankowska
Wrocław Medical University, Wrocław, PL
Fadi Jouhra
St George’s Hospital, London, UK
Dr David Sim Kheng Leng
National Heart Centre Singapore, SG
Dr Tammy Lyn Kindel
Medical College of Wisconsin, Wisconsin, US
Prof Friedrich Köhler
Charité Campus Mitte, Berlin, DE
Prof Mitja Lainscak
University of Ljubljana, Ljubljana, SI
Prof Béla Merkely
Semmelweis University Heart and Vascular Center, Budapest, HU
Dr Alanna A. Morris
Emory University School of Medicine, Georgia, US
Dr Milton Packer
Baylor University Medical Center, Texas, US
Dr Ambarish Pandey
University of Texas Southwestern Medical Center, Texas, US
Dr Leor Perl
Rabin Medical Center, Petah Tikva, IL
Prof Mark Petrie
University of Glasgow, Glasgow, UK
Dr Ileana Piña
Wayne State University, Michigan, US
Prof Piotr Ponikowski
Wrocław Medical University, Wrocław, PL
Dr Harish Ramakrishna
Mayo Clinic, Minnesota, US
Prof Giuseppe Rosano
St George's University of London, London, UK
Prof Clara Ines Saldarriaga
Cardiovascular Clinic Santa Maria, Medellin, CO
Prof Naveed Sattar
University of Glasgow, Glasgow, UK
Dr Gianluigi Savarese
Karolinska Institute, Stockholm, SE
Prof Petar Seferović
Belgrade University, Belgrade, RS
Dr Rishi Sethi
King George's Medical University, Uttar Pradesh, IN
Altamash Y. Shaikh
Saifee Hospital, Mumbai, IN
Prof Horst Sievert
CardioVascular Center Frankfurt, Frankfurt, DE
Prof Philippe Gabriel Steg
Hopital Bichat, Paris, FR
Prof Gregg Stone
Icahn School of Medicine at Mount Sinai, New York, US
Dr John Teerlink
San Francisco Veterans Affairs Medical Center, California, US
Prof Thomas Thum
Institute for Molecular and Translational Therapeutic Strategies, Hannover, DE
Prof Hiroyuki Tsutsui
Kyushu University, Fukuoka, JP
Dr Katherine Tuttle
University of Washington, Washington, US
Dr Muthiah Vaduganathan
Brigham and Women’s Hospital, Massachusetts, US
Dr Harriette Van Spall
McMaster University, Hamilton, CA
Dr Subodh Verma
St. Michael's Hospital, Toronto, CA
Prof Ralph Stephan von Bardeleben
University Medical Center of Mainz, Mainz, DE
Prof Stephan von Haehling
University Medicine Göttingen, Göttingen, DE
Prof Mehmet Birhan Yilmaz
Dokuz Eylul University, Izmir, TR
Dr Faiez Zannad
Academic Hospital (CHU), Nancy, FR
Prof Yuhui Zhang
Fuwai Hospital, Beijing, CN
Register now
Programme
(Please note this programme is subject to change)
Friday, October 14, 2022 (Day 1)
Implementing the 4 foundational therapies in clinical practice
Chairs: John Atherton and Marianna Adamo• At discharge: Piotr Ponikowski
• In outpatients clinic: Mark Petrie
• At home: Gianluigi Savarese
• Can biomarkers help here?: Kieran Docherty
• Panel discussion
Managing your HF patients with comorbidities (part 1)
Chairs: Yuhui Zhang and David Sim Kheng Leng• Coronary artery disease & angina: Giuseppe Rosano
• Hypertension: Vijay Chopra
• Ventricular arrhythmia: Béla Merkely
• Atrial fibrillation: John Camm
• Panel discussion
Using SGLT2 in your patients: practical considerations
Chairs: Philippe Gabriel Steg and Shelley Zieroth• When to use them: Milton Packer
• Implementation of SGLT2i across the spectrum of heart failure: Muthiah Vaduganathan
• Managing the side effects: Cecilia Bahit
• When not to use them: Subodh Verma
• Panel discussion
Managing your HF patients with comorbidities (part 2)
Chairs: Giuseppe Galati and Altamash Y. Shaikh• Iron deficiency: Ewa Jankowska
• Cardiorenal disease: George L. Bakris
• Frailty: Stephan von Haehling
• Hyperkalemia: Javed Butler
• Panel discussion
Managing side effects of HF drugs
Chairs: Ambarish Pandey and Mitja Lainscak• Abnormal eGFR levels: Faiez Zannad
• Infection: Justin Ezekowitz
• Drug-to-drug interactions: Ileana Piña
• Hypotension: Harriette Van Spall
• Panel discussion
How to manage the obese patient with HF
Chairs: Antonio Ceriello and Naveed Sattar• GLP1 agonist: Stefan Anker
• Bariatric surgery: Tammy Lyn Kindel
• Exercise: Andrew Coats
• Lifestyle and education – the GP perspective: Jean-Philippe Minart
• Panel discussion
Saturday, October 15, 2022 (Day 2)
New technologies to manage your patients
Chairs: Vijay Chopra and Rishi Sethi• Classic telemedicine: Friedrich Köhler
• Update on pulmonary artery pressure sensing: Jasper J. Brugts
• Left atrial pressure sensing: William Abraham
• Digital health care solutions for proactive management of HF: Leor Perl
• Panel discussion
New technologies to treat your patients
Chairs: Sajid Ansari and Fadi Jouhra• CCM in clinical practice: Marat Fudim
• Barostimulation: Johann Bauersachs
• IntraAtrial shunt devices: William Abraham
• New miRNA drugs: Thomas Thum
• Panel discussion
Comparing European and US recent guidelines
Chair: Stefan Anker• HFpEF: Antoni Bayes-Genis
• HFrEF: Biykem Bozkurt
• Acute HF: Gerasimos Filippatos
• Unknown epidemiology of heart failure - Why we need a new universal definition: John Cleland
• Panel discussion
How to implement these GLS in ambulatory patients around the world
Chairs: Katherine Tuttle and Mehmet Birhan Yilmaz• Europe: Petar Seferović
• India: Sivadasanpillai Harikrishnan
• China: Yuhui Zhang
• Middle East: Magdy Abdelhamid
• South America: Clara Ines Saldarriaga
• Japan: Hiroyuki Tsutsui
• Panel discussion
Managing the HF patient with valvular heart disease
Chairs: Stephen Greene• Update on Mitraclip: Gregg Stone
• The place of Carillon: Horst Sievert
• Managing tricuspid regurgitation: Harish Ramakrishna
• Targeting atrial FMR: Ralph Stephan von Bardeleben
• Panel discussion
Managing the patient with worsening and advanced HF
Chairs: Marisa G. Crespo-Leiro and Ovidiu Chioncel• Definition of WHF and disease burden: Alanna A. Morris
• Therapeutic options: vericiguat: Shelley Zieroth
• Therapeutic options: OM: John Teerlink
• Patients with low blood pressure: Gerasimos Filippatos
• Panel discussion
Target Audience
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
Learning Objectives
- Review the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) as one of the leading causes of disability and mortality worldwide
- Understand the latest guideline recommendations and discuss their applicability according to patients phenotypes
- Discuss the implementation in clinical practice of the four foundational therapies and additional drugs and devices to improve patient outcomes
- Develop a comprehensive understanding of best practices for the screening, diagnosis and management of the patient with heart failure and comorbidities
- Translate the findings of recent studies and guidelines into optimal patient management in the regional contexts
Sponsors:
If you’re interested in becoming an educational partner or sponsor at this event, please contact sales@radcliffe-group.com
About Translational Medicine Academy
Our ambition at the Translational Medicine Academy® (TMA) is to bring medical findings from bench to bedside and into the working lives of physicians and the care of patients. In seeking to improve therapeutic approaches, TMA works with its International Scientific Advisory Board on Critical Mission Areas® of public health importance in domains where there are educational shortcomings among physicians and unmet healthcare needs among patients.
Gathered around a Scientific Advisory Board of experts, the Translational Medicine Academy is an international non-profit Foundation with headquarter in Basel, and offices in Paris, and the US. TMA’s funding includes private donations from individuals and educational grants from governments, non-governmental organizations and corporations.
For more information on TMA, please visit www.tmacademy.org.
About Radcliffe Cardiology
We are Radcliffe, a knowledge network for the cardiovascular community.
We’re here to bring cardiovascular knowledge, insight and innovation to life for clinicians around the world, using our communications and creative expertise, our platforms and connections across the community to help transform theory into practice faster and more effectively.
We bring medical knowledge to life
From great science writing and smart journal editing, the curation of evidence based and peer-reviewed content, to engaging new formats that cut through the noise, we believe that communication is at the heart of great healthcare.
Our work is underpinned by 3 core principles:
- We build on the best science
- We work hands-on with our community
- We bring fresh thinking
Our promise is that we’ll equip you with the latest knowledge and skills you need, to do the best for your patients.
For more information on Radcliffe Cardiology, please visit www.radcliffecardiology.com.
Please contact events@radcliffe-group.com should you have any queries.